[1. Camm AJ, Lip GYH, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012;33:2719 -47. doi: 10.1093/eurheartj/ehs253]Search in Google Scholar
[2. Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012;141:e152S-e184S. doi: 10.1378/chest.11-2295.]Search in Google Scholar
[3. Garcia D, Crowther MA, Ageno W. Practical management of coagulopathy associated with warfarin. BMJ. 2010;340:c1813. doi: 10.1136/bmj.c1813.]Search in Google Scholar
[4. Ufer M. Comparative Pharmacokinetics of Vitamin K Antagonists: warfarin, phenprocoumon and acenocoumarol. Clin Pharmacokinet. 2005;44:1227-46. doi: 10.2165/00003088-200544120-00003]Search in Google Scholar
[5. Villena Garrido V, Cases Viedma E, Fernandez Villar A, et al. Recommendations of diagnosis and treatment of pleural effusion. Update. Arch Bronconeumol. 2014;50:235-49. doi: 10.1016/j.arbres.2014.01.016.]Search in Google Scholar
[6. Huggins JT, Sahn SA. Causes and management of pleural fibrosis. Respirology. 2004;9:441-7. doi: 10.1111/j.1440-1843.2004.00630.x]Search in Google Scholar
